In this landscape, imeglimin stands out by exhibiting a dual effect on both glucose‐stimulated insulin secretion highlighted in preclinical11 and in T2D patients,13 and insulin sensitivity in muscle and liver in preclinical models,18 associated with a preclinical cardiorenal benefit.19 This evidence concerns the gene INS and type 2 diabetes mellitus.